Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: Real-world results from the Italian multicenter UPARAREMUS study
Arthritis Research & Therapy 2025;27:203 Doi: 10.1186/s13075-025-03671-z
Diamanti et al. showed that after 12 months of UPA treatment, a substantial proportion of RA patients achieved combined clinical and US remission, independent of prior bDMARD use or monotherapy. In the preliminary data from the UPARAREMUS study, authors reported efficacy of UPA in achieving both clinical and US remission up to 24 weeks in 60 RA patients.